A BILL 
To establish programs related to prevention of prescription 
opioid misuse, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Addiction Prevention 
4
and Responsible Opioid Practices Act’’. 
5
00:06 Aug 09, 2020
H7701
2 
•HR 7701 IH
SEC. 2. FEDERAL LICENSURE OF PHARMACEUTICAL REP-
1
RESENTATIVES 
WHO 
PROMOTE 
CERTAIN 
2
OPIOIDS. 
3
Subchapter E of chapter V of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 360bbb et seq.) is 
5
amended by adding at the end the following: 
6
‘‘SEC. 569E. FEDERAL LICENSURE OF PHARMACEUTICAL 
7
REPRESENTATIVES WHO PROMOTE CERTAIN 
8
OPIOIDS. 
9
‘‘(a) IN GENERAL.—The Secretary, in consultation 
10
with the Attorney General, shall establish a licensure pro-
11
gram for pharmaceutical representatives described in sub-
12
section (b). 
13
‘‘(b) LICENSURE PROGRAM.— 
14
‘‘(1) REQUIREMENT.—Beginning on July 1, 
15
2021, no individual described in paragraph (2) may 
16
engage in the marketing or promoting of opioid 
17
drugs unless such individual is licensed under this 
18
section. 
19
‘‘(2) INDIVIDUALS
REQUIRED
TO
OBTAIN
LI-
20
CENSURE.—An individual required to obtain a li-
21
cense under this section is any individual who, on 
22
behalf of a drug manufacturer, engaged, on more 
23
than 15 days in a calendar year, in the marketing 
24
or promotion to health care professionals, including 
25
educational or sales communications, meetings or 
26
00:06 Aug 09, 2020
H7701
3 
•HR 7701 IH
paid events, and the provision of goods, gifts, and 
1
samples, of any opioid drug (other than methadone) 
2
that is listed in schedule II of section 202(c) of the 
3
Controlled Substances Act. 
4
‘‘(3) LICENSURE PERIOD.—Each license issued 
5
under this section shall be valid for 3 years, and 
6
may be renewed for additional 3-year periods. 
7
‘‘(c) REQUIREMENTS.—An individual required to ob-
8
tain a license under this section shall— 
9
‘‘(1) submit to the Secretary, at such time and 
10
in such manner as the Secretary may require— 
11
‘‘(A) such information as the Secretary 
12
may require; and 
13
‘‘(B) a registration fee in the amount of 
14
$3,000; 
15
‘‘(2) certify that such individual has completed 
16
training on ethics, pharmaceutical marketing regula-
17
tions, the ‘CDC Guidelines for Prescribing Opioids 
18
for Chronic Pain’, published by the Centers for Dis-
19
ease Control and Prevention in 2016 (or any suc-
20
cessor document) or the ‘FDA Blueprint for Pre-
21
scriber Education for Extended-Release and Long- 
22
Acting Opioid Analgesics’, and applicable Federal 
23
laws pertaining to drug marketing, labeling, and 
24
clinical trials, as the Secretary may require; 
25
00:06 Aug 09, 2020
H7701
4 
•HR 7701 IH
‘‘(3) certify that such individual will not engage 
1
in any illegal, fraudulent, misleading, or other decep-
2
tive marketing of schedule II opioid drugs; and 
3
‘‘(4) file with the Secretary annual reports dis-
4
closing the names of providers visited and any drug 
5
samples or gifts such individual gives any such pro-
6
vider. 
7
‘‘(d) 
MANUFACTURER
REPORTING
REQUIRE-
8
MENTS.—The manufacturer who employs or contracts 
9
with any individual required to obtain a license under this 
10
section shall include in reports required under section 
11
1128G of the Social Security Act the name of each such 
12
licensed individual that provides payments or other trans-
13
fers of value required to be reported under such section 
14
1128G that relates to an opioid drug that is listed in 
15
schedule II of the Controlled Substances Act.’’. 
16
SEC. 3. WITHDRAWAL OF APPROVAL OF CERTAIN OPIOIDS. 
17
(a) IN GENERAL.—Notwithstanding any other provi-
18
sion of law, any ultra-high-dose opioid shall be considered 
19
a drug that presents an imminent hazard to the public 
20
health within the meaning of section 505(e) of the Federal 
21
Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), and 
22
the Secretary of Health and Human Services shall sus-
23
pend the approval of such drug, in accordance with such 
24
section 505(e). 
25
00:06 Aug 09, 2020
H7701
5 
•HR 7701 IH
(b) DEFINITION.—In this section, the term ‘‘ultra- 
1
high-dose opioid’’ means an opioid drug for which the 
2
daily dosage provided for in the approved label exceeds 
3
the morphine milligram equivalents per day outlined in the 
4
report entitled ‘‘CDC Guidelines for Prescribing Opioids 
5
for Chronic Pain’’, published by the Centers for Disease 
6
Control and Prevention in 2016 (or any successor docu-
7
ment). 
8
SEC. 4. CONTINUING MEDICAL EDUCATION AND PRESCRIP-
9
TION DRUG MONITORING PROGRAM REG-
10
ISTRATION FOR PRESCRIBERS. 
11
Section 303 of the Controlled Substances Act (21 
12
U.S.C. 823) is amended— 
13
(1) by redesignating subsection (k) as sub-
14
section (l); and 
15
(2) by inserting after subsection (j) the fol-
16
lowing: 
17
‘‘(k)(1) The Attorney General shall not register, or 
18
renew the registration of, a practitioner under subsection 
19
(f) who is licensed under State law to prescribe controlled 
20
substances in schedule II, III, or IV, unless the practi-
21
tioner submits to the Attorney General, for each such reg-
22
istration or renewal request, a written certification that— 
23
‘‘(A)(i) the practitioner has, during the 1-year 
24
period preceding the registration or renewal request, 
25
00:06 Aug 09, 2020
H7701
6 
•HR 7701 IH
completed a training program described in para-
1
graph (2); or 
2
‘‘(ii) the practitioner, during the applicable reg-
3
istration period, will not prescribe such controlled 
4
substances in amounts in excess of a 72-hour supply 
5
(for which no refill is available); and 
6
‘‘(B) the practitioner has registered with the 
7
prescription drug monitoring program of the State 
8
in which the practitioner practices, if the State has 
9
such program. 
10
‘‘(2) A training program described in this paragraph 
11
is a training program that— 
12
‘‘(A) follows the best practices for pain manage-
13
ment, as described in the ‘Guideline for Prescribing 
14
Opioids for Chronic Pain’ as published by the Cen-
15
ters for Disease Control and Prevention in 2016, or 
16
any successor thereto, or the ‘FDA Blueprint for 
17
Prescriber Education for Extended-Release and 
18
Long-Acting Opioid Analgesics’ as published by the 
19
Food and Drug Administration in 2017, or any suc-
20
cessor thereto; 
21
‘‘(B) includes information on— 
22
‘‘(i) recommending non-opioid and non- 
23
pharmacological therapy; 
24
00:06 Aug 09, 2020
H7701
7 
•HR 7701 IH
‘‘(ii) establishing treatment goals and eval-
1
uating patient risks; 
2
‘‘(iii) prescribing the lowest dose and few-
3
est number of pills considered effective; 
4
‘‘(iv) addictive and overdose risks of 
5
opioids; 
6
‘‘(v) diagnosing and managing substance 
7
use disorders, including linking patients to evi-
8
dence-based treatment; 
9
‘‘(vi) identifying narcotics-seeking behav-
10
iors; and 
11
‘‘(vii) using prescription drug monitoring 
12
programs; and 
13
‘‘(C) is approved by the Secretary.’’. 
14
SEC. 5. REPORT ON PRESCRIBER EDUCATION COURSES 
15
FOR MEDICAL AND DENTAL STUDENTS. 
16
Each school of medicine, school of osteopathic medi-
17
cine, and school of dentistry participating in a program 
18
under title IV of the Higher Education Act of 1965 (20 
19
U.S.C. 1070a et seq.), as a condition for such participa-
20
tion, shall submit an annual report to the Secretary of 
21
Education and the Secretary of Health and Human Serv-
22
ices on any prescriber education courses focused specifi-
23
cally on pain management and responsible opioid pre-
24
scribing practices that such school requires students to 
25
00:06 Aug 09, 2020
H7701
8 
•HR 7701 IH
take, and whether such courses are consistent with the 
1
most recently published version of the ‘‘Guideline for Pre-
2
scribing Opioids for Chronic Pain’’ of the Centers for Dis-
3
ease Control and Prevention or the ‘‘FDA Blueprint for 
4
Prescriber Education for Extended-Release and Long-Act-
5
ing Opioid Analgesics’’, as published by the Food and 
6
Drug Administration in 2017. The Secretary of Education 
7
and the Secretary of Health and Human Services shall 
8
compile the reports submitted by such schools and submit 
9
an annual summary of such reports to Congress. 
10
SEC. 6. REQUIREMENTS UNDER PRESCRIPTION DRUG MON-
11
ITORING PROGRAMS. 
12
(a) IN GENERAL.—Beginning 1 year after the date 
13
of enactment of this Act, each State that receives funding 
14
under any of the programs described in subsection (c) 
15
shall— 
16
(1) require practitioners, or their designees, in 
17
the State to consult the database of the prescription 
18
drug monitoring program before writing prescrip-
19
tions for controlled substances (as such term is de-
20
fined in section 102 of the Controlled Substances 
21
Act (21 U.S.C. 802)) in schedule II, III, or IV 
22
under section 202 of such Act (21 U.S.C. 812); 
23
(2) require dispensers of controlled substances 
24
in schedule II, III, or IV, or their designees, to input 
25
00:06 Aug 09, 2020
H7701
9 
•HR 7701 IH
data into the database of the prescription drug mon-
1
itoring program within 24 hours of filling a quali-
2
fying prescription, as required by the Attorney Gen-
3
eral and the Secretary of Health and Human Serv-
4
ices, including patient identifier information, the na-
5
tional drug code of the dispensed drug, date of dis-
6
pensing the drug, quantity and dosage of the drug 
7
dispensed, form of payment, Drug Enforcement Ad-
8
ministration registration number of the practitioner, 
9
Drug Enforcement Administration registration num-
10
ber of the dispenser; 
11
(3) allow practitioners and dispensers to des-
12
ignate other appropriate individuals to act as agents 
13
of such practitioners and dispensers for purposes of 
14
obtaining and inputing data from the database for 
15
purposes of complying with paragraphs (1) and (2), 
16
as applicable; 
17
(4) provide informational materials for practi-
18
tioners and dispensers to identify and refer patients 
19
with possible substance use disorders to professional 
20
treatment specialists; 
21
(5) establish formal data sharing agreements to 
22
foster electronic connectivity with the prescription 
23
drug monitoring programs of each State (if such 
24
State has such a program) with which the State 
25
00:06 Aug 09, 2020
H7701
10 
•HR 7701 IH
shares a border, to facilitate the exchange of infor-
1
mation through an established technology architec-
2
ture that ensures common data standards, privacy 
3
protection, and secure and streamlined information 
4
sharing; 
5
(6) authorize direct access to the State’s data-
6
base of the prescription drug monitoring program to 
7
all State law enforcement agencies, State boards re-
8
sponsible for the licensure, regulation, or discipline 
9
of practitioners, pharmacists, or other persons au-
10
thorized to prescribe, administer, or dispense con-
11
trolled substances; and 
12
(7) in order to enhance accountability in pre-
13
scribing and dispensing patterns, not fewer than 4 
14
times per year, proactively provide informational re-
15
ports on aggregate trends and individual outliers, 
16
based on information available through the State 
17
prescription drug monitoring program to— 
18
(A) the State entities and persons de-
19
scribed in paragraph (6); and 
20
(B) the Medicaid agency and the depart-
21
ment of public health of the State. 
22
(b) TRANSPARENCY IN PRESCRIBING PRACTICES AND 
23
INTERVENTION FOR HIGH PRESCRIBERS.— 
24
00:06 Aug 09, 2020
H7701
11 
•HR 7701 IH
(1) STATE
REPORTING
REQUIREMENT.—Each 
1
State that receives funding under any of the pro-
2
grams described in subsection (c) shall, twice per 
3
year, submit to the Secretary of Health and Human 
4
Services and the Administrator of the Drug Enforce-
5
ment Administration— 
6
(A) a list of all practitioners and dis-
7
pensers who, in the applicable reporting period, 
8
have prescribed or dispensed schedule II, III, or 
9
IV opioids in the State; 
10
(B) the amount of schedule II, III, or IV 
11
opioids that were prescribed and dispensed by 
12
each individual practitioner and dispenser de-
13
scribed in subparagraph (A); and 
14
(C) any additional information that the 
15
Secretary and Administrator may require to 
16
support surveillance and evaluation of trends in 
17
prescribing or dispensing of schedule II, III, or 
18
IV opioids, or to identify possible non-medical 
19
use and diversion of such substances. 
20
(2) ANNUAL REPORT.—Not later than 1 year 
21
after the date of enactment of this Act, and annually 
22
thereafter, the Secretary of Health and Human 
23
Services, in consultation with the Administrator of 
24
the Drug Enforcement Administration, the Secretary 
25
00:06 Aug 09, 2020
H7701
12 
•HR 7701 IH
of Defense, the Secretary of Veterans Affairs, and 
1
the Director of the Indian Health Service, shall sub-
2
mit to Congress, and make public, a report identi-
3
fying outliers among the medical specialties and geo-
4
graphic areas with the highest rates of opioid pre-
5
scribing in the Nation, by zip code. 
6
(3) DEVELOPMENT OF ACTION PLAN.— 
7
(A) INITIAL PLAN.—Not later than 1 year 
8
after the date of enactment of this Act, the Sec-
9
retary of Health and Human Services, in con-
10
sultation with the Administrator of the Drug 
11
Enforcement Administration, the Secretary of 
12
Defense, the Secretary of Veterans Affairs, and 
13
the Director of the Indian Health Service, shall 
14
submit to Congress a plan of action, including 
15
warning letters and enforcement mechanisms, 
16
for addressing outliers in opioid prescribing 
17
practices and ensuring an adequate Federal re-
18
sponse to protect the public health. 
19
(B) UPDATED
PLAN.—The Secretary of 
20
Health and Human Services shall submit to 
21
Congress updates to the plan of action de-
22
scribed in subparagraph (A), as such Secretary, 
23
in consultation with the heads of agencies de-
24
00:06 Aug 09, 2020
H7701
13 
•HR 7701 IH
scribed in such subparagraph, determines ap-
1
propriate. 
2
(c) PROGRAMS
DESCRIBED.—The programs de-
3
scribed in this subsection are— 
4
(1) the Harold Rogers Prescription Drug Moni-
5
toring Program established under the Departments 
6
of Commerce, Justice, and State, the Judiciary, and 
7
Related Agencies Appropriations Act, 2002 (Public 
8
Law 107–77; 115 Stat. 748); 
9
(2) the controlled substance monitoring pro-
10
gram under section 399O of the Public Health Serv-
11
ice Act (42 U.S.C. 280g–3); 
12
(3) the Prescription Drug Overdose: Prevention 
13
for States program of the Centers for Disease Con-
14
trol and Prevention; 
15
(4) the Prescription Drug Overdose: Data-Driv-
16
en Prevention Initiative of Centers for Disease Con-
17
trol and Prevention; 
18
(5) the Enhanced State Opioid Overdose Sur-
19
veillance program of the Centers for Disease Control 
20
and Prevention; 
21
(6) the opioid grant program under section 
22
1003 of the 21st Century Cures Act (Public Law 
23
114–255); and 
24
00:06 Aug 09, 2020
H7701
14 
•HR 7701 IH
(7) the State Opioid Response Grant program 
1
described under the heading ‘‘SUBSTANCE
ABUSE 
2
TREATMENT’’ under the heading ‘‘SUBSTANCE 
3
ABUSE AND MENTAL HEALTH SERVICES ADMINIS-
4
TRATION’’ of title II of division A of the Further 
5
Consolidated Appropriations Act, 2020 (Public Law 
6
116–94). 
7
(d) DEFINITIONS.—In this section, the terms ‘‘dis-
8
penser’’ and ‘‘practitioner’’ have the meanings given such 
9
terms in section 102 of the Controlled Substances Act (21 
10
U.S.C. 802). 
11
SEC. 7. INTEROPERABILITY OF CERTIFIED HEALTH INFOR-
12
MATION TECHNOLOGY. 
13
Section 3001(c)(5) of the Public Health Service Act 
14
(42 U.S.C. 300jj–11(c)(5)) is amended by adding at the 
15
end the following: 
16
‘‘(F) INTEROPERABILITY.—Beginning on 
17
January 1, 2021, the National Coordinator 
18
shall not certify electronic health records as 
19
health information technology that is in compli-
20
ance with applicable certification criteria under 
21
this paragraph unless such technology is inter-
22
operable with the prescription drug monitoring 
23
programs of each State that, at the time of the 
24
00:06 Aug 09, 2020
H7701
15 
•HR 7701 IH
request for such certification, has such a pro-
1
gram.’’. 
2
SEC. 8. STUDIES RELATED TO OVERDOSE DISCHARGE AND 
3
FOLLOW-UP POLICIES. 
4
(a) STUDY.—Not later than January 1, 2021, the 
5
Secretary of Health and Human Services shall— 
6
(1) conduct a study on the scope and cir-
7
cumstances of non-fatal opioid overdoses, the policies 
8
and procedures that States, health care systems, and 
9
first responders have implemented; and 
10
(2) in partnership with stakeholder organiza-
11
tions with subject matter expertise, establish guide-
12
lines for hospital procedures following non-fatal 
13
opioid overdose and the administration of overdose 
14
reversal medication. 
15
(b) STUDY AND DEVELOPMENT OF QUALITY MEAS-
16
URES UNDER MEDICARE RELATED TO OPIOID ABUSE 
17
AND SUBSTANCE USE DISORDER.—Section 1890A(e) of 
18
the Social Security Act (42 U.S.C. 1395aaa–1(e)) is 
19
amended— 
20
(1) by striking ‘‘MEASURES.—The Adminis-
21
trator’’ and inserting ‘‘MEASURES.— 
22
‘‘(1) IN GENERAL.—The Administrator’’; and 
23
(2) by adding at the end the following new 
24
paragraph: 
25
00:06 Aug 09, 2020
H7701
16 
•HR 7701 IH
‘‘(2) STUDY AND DEVELOPMENT OF QUALITY 
1
MEASURES RELATED TO OPIOID ABUSE AND SUB-
2
STANCE USE DISORDER.—Beginning not later than 
3
1 year after the date of enactment of this para-
4
graph, the Administrator of the Center for Medicare 
5
& Medicaid Services shall study, and through con-
6
tracts develop, in coordination with appropriate sub-
7
ject matter organizations (such as the entity with a 
8
contract under section 1890), for use under this Act, 
9
quality measures related to standards of care for 
10
treating individuals with non-fatal opioid overdose, 
11
discharge procedures, and linkages to appropriate 
12
substance use disorder treatment and community 
13
support services.’’. 
14
SEC. 9. MEDICAID OPIOID DRUG MAPPING TOOL. 
15
(a) IN GENERAL.—The Secretary of Health and 
16
Human Services shall create an interactive opioid drug 
17
mapping tool, which shall be made publicly available on 
18
the internet website of the Centers for Medicare & Med-
19
icaid Services, showing prescribing practices of providers 
20
that participate in State Medicaid programs and geo-
21
graphic comparisons, at the State, county, and ZIP code 
22
levels, of de-identified opioid prescription claims made 
23
under State Medicaid programs under title XIX of the So-
24
cial Security Act (42 U.S.C. 1396 et seq.). 
25
00:06 Aug 09, 2020
H7701
17 
•HR 7701 IH
(b) COLLECTION OF DATA FROM STATES.—The Sec-
1
retary of Health and Human Services may request from 
2
States such data as the Secretary determines necessary 
3
to create the opioid mapping tool described in subsection 
4
(a). 
5
SEC. 10. NATIONAL ACADEMIES STUDY. 
6
(a) STUDY.—The Secretary of Health and Human 
7
Services shall enter into a contract with the National 
8
Academies of Science, Engineering, and Medicine (re-
9
ferred to in this section as the ‘‘National Academies’’) to 
10
carry out a study on the addition of coverage under the 
11
Medicare program under title XVIII of the Social Security 
12
Act of alternative treatment modalities (such as integra-
13
tive medicine, including acupuncture and exercise therapy, 
14
neural stimulation, biofeedback, radiofrequency ablation, 
15
and trigger point injections) furnished to Medicare bene-
16
ficiaries who suffer from acute or chronic lower back pain. 
17
Such study shall, pursuant to the contract under this 
18
paragraph, include an analysis of— 
19
(1) scientific research on the short-term and 
20
long-term impact of the addition of such coverage on 
21
clinical efficacy for pain management of such bene-
22
ficiaries; 
23
00:06 Aug 09, 2020
H7701
18 
•HR 7701 IH
(2) whether the lack of Medicare coverage for 
1
alternative treatment modalities impacts the volume 
2
of opioids prescribed for beneficiaries; and 
3
(3) the cost to the Medicare program of the ad-
4
dition of such coverage to treat pain and mitigate 
5
the progression of chronic pain, as weighed against 
6
the cost of opioid use disorder, overdose, readmis-
7
sion, subsequent surgeries, and utilization and ex-
8
penditures under parts B and D of such title. 
9
(b) REPORT.—Not later than 1 year after the date 
10
of enactment of this Act, pursuant to the contract under 
11
subsection (a), the National Academies shall submit to 
12
Congress a report on the study under subsection (a). 
13
(c) AUTHORIZATION OF APPROPRIATIONS.—To carry 
14
out this section, there are authorized to be appropriated 
15
such sums as may be necessary. 
16
SEC. 11. EXCISE TAX ON OPIOID PAIN RELIEVERS. 
17
(a) IN GENERAL.—Subchapter E of chapter 32 of the 
18
Internal Revenue Code of 1986 is amended by adding at 
19
the end the following new section: 
20
‘‘SEC. 4192. OPIOID PAIN RELIEVERS. 
21
‘‘(a) IN GENERAL.—There is hereby imposed on the 
22
manufacturer or producer of any taxable active opioid a 
23
tax equal to the amount determined under subsection (b). 
24
00:06 Aug 09, 2020
H7701
19 
•HR 7701 IH
‘‘(b) AMOUNT DETERMINED.—The amount deter-
1
mined under this subsection with respect to a manufac-
2
turer or producer for a calendar year is 1 cent per milli-
3
gram of taxable active opioid in the production or manu-
4
facturing quota determined for such manufacturer or pro-
5
ducer for the calendar year under section 306 of the Con-
6
trolled Substances Act (21 U.S.C. 826). 
7
‘‘(c) TAXABLE ACTIVE OPIOID.—For purposes of this 
8
section— 
9
‘‘(1) IN GENERAL.—The term ‘taxable active 
10
opioid’ means any controlled substance (as defined 
11
in section 102 of the Controlled Substances Act (21 
12
U.S.C. 802), as in effect on the date of the enact-
13
ment of this section) manufactured in the United 
14
States which is opium, an opiate, or any derivative 
15
thereof. 
16
‘‘(2) EXCLUSIONS.— 
17
‘‘(A) OTHER INGREDIENTS.—In the case 
18
of a product that includes a taxable active 
19
opioid and another ingredient, subsection (a) 
20
shall apply only to the portion of such product 
21
that is a taxable active opioid. 
22
‘‘(B) DRUGS USED IN ADDICTION TREAT-
23
MENT.—The term ‘taxable active opioid’ shall 
24
not include any controlled substance (as so de-
25
00:06 Aug 09, 2020
H7701
20 
•HR 7701 IH
fined) which is used exclusively for the treat-
1
ment of opioid addiction as part of a medica-
2
tion-assisted treatment.’’. 
3
(b) CLERICAL AMENDMENTS.— 
4
(1) The heading of subchapter E of chapter 32 
5
of the Internal Revenue Code of 1986 is amended by 
6
striking 
‘‘Medical 
Devices’’ 
and 
inserting 
7
‘‘Other Medical Products’’. 
8
(2) The table of subchapters for chapter 32 of 
9
such Code is amended by striking the item relating 
10
to subchapter E and inserting the following new 
11
item: 
12
‘‘SUBCHAPTER E. OTHER MEDICAL PRODUCTS’’. 
(3) The table of sections for subchapter E of 
13
chapter 32 of such Code is amended by adding at 
14
the end the following new item: 
15
‘‘Sec. 4192. Opioid pain relievers.’’. 
(c) EFFECTIVE DATE.—The amendments made by 
16
this section shall apply to calendar years beginning after 
17
the date of the enactment of this Act. 
18
SEC. 12. OPIOID CONSUMER ABUSE REDUCTION PROGRAM. 
19
(a) OPIOID TAKE-BACK PROGRAM.—Section 302 of 
20
the Controlled Substances Act (21 U.S.C. 822) is amend-
21
ed by adding at the end the following: 
22
00:06 Aug 09, 2020
H7701
21 
•HR 7701 IH
‘‘(h)(1) The Attorney General shall establish a na-
1
tional take-back program for the safe and environmentally 
2
responsible disposal of controlled substances. 
3
‘‘(2) In establishing the take-back program required 
4
under paragraph (1), the Attorney General— 
5
‘‘(A) shall consult with the Secretary and the 
6
Administrator of the Environmental Protection 
7
Agency; and 
8
‘‘(B) may coordinate with States, law enforce-
9
ment agencies, water resource management agencies, 
10
manufacturers, practitioners, pharmacists, public 
11
health entities, transportation and incineration serv-
12
ice contractors, and other entities and individuals, as 
13
appropriate. 
14
‘‘(3) The take-back program established under para-
15
graph (1)— 
16
‘‘(A) shall— 
17
‘‘(i) ensure appropriate geographic dis-
18
tribution so as to provide— 
19
‘‘(I) reasonably convenient and equi-
20
table access to permanent take-back loca-
21
tions, including not less than 1 disposal 
22
site for every 25,000 residents and not less 
23
than 1 physical disposal site per town, city, 
24
00:06 Aug 09, 2020
H7701
22 
•HR 7701 IH
county, or other unit of local government, 
1
where possible; and 
2
‘‘(II) periodic collection events and 
3
mail-back programs, including public no-
4
tice of such events and programs, as a sup-
5
plement to the permanent take-back loca-
6
tions described in subclause (I), particu-
7
larly in areas in which the provision of ac-
8
cess to such locations at the level described 
9
in that subclause is not possible; 
10
‘‘(ii) establish a process for the accurate 
11
cataloguing and reporting of the quantities of 
12
controlled substances collected; and 
13
‘‘(iii) include a public awareness campaign 
14
and education of practitioners and pharmacists; 
15
and 
16
‘‘(B) may work in coordination with State and 
17
locally implemented public and private take-back 
18
programs. 
19
‘‘(4) From time to time, beginning in the second cal-
20
endar year that begins after the date of enactment of this 
21
subsection, the Secretary of the Treasury shall transfer 
22
from the general fund of the Treasury an amount equal 
23
to one-half of the total amount of taxes collected under 
24
section 4192 of the Internal Revenue Code of 1986 to the 
25
00:06 Aug 09, 2020
H7701
23 
•HR 7701 IH
Attorney General to carry out this subsection. Amounts 
1
transferred under this subparagraph shall remain avail-
2
able until expended.’’. 
3
(b) FUNDING OF SUBSTANCE ABUSE PROGRAMS.— 
4
From time to time, beginning in the second calendar year 
5
that begins after the date of enactment of this Act, the 
6
Secretary of the Treasury shall transfer from the general 
7
fund of the Treasury an amount equal to one-half of the 
8
total amount of taxes collected under section 4192 of the 
9
Internal Revenue Code of 1986, as added by this Act, to 
10
the Director of the Center for Substance Abuse Treatment 
11
of the Substance Abuse and Mental Health Services Ad-
12
ministration for programs of the Center, including the 
13
Block Grants for Prevention and Treatment of Substance 
14
Abuse program under subpart II of part B of title XIX 
15
of the Public Health Service Act (42 U.S.C. 300x–21 et 
16
seq.) and Programs of Regional and National Significance. 
17
Amounts transferred under this subsection shall remain 
18
available until expended. 
19
SEC. 13. GAO STUDY. 
20
Not later than 1 year after the date of enactment 
21
of this Act, the Comptroller General of the United States 
22
shall— 
23
(1) conduct a study examining the coverage of-
24
fered under commercial health insurance plans and 
25
00:06 Aug 09, 2020
H7701
24 
•HR 7701 IH
reimbursement rates under the Medicare program 
1
and State Medicaid plans with respect to— 
2
(A) substance use disorder treatment serv-
3
ices, as compared to other health services, and 
4
how any disparity identified under this para-
5
graph may contribute to differences in salary 
6
and turnover among substance abuse disorder 
7
providers; and 
8
(B) rates of coverage or reimbursement, as 
9
applicable, for substance abuse disorder services 
10
provided via telehealth, as compared to such 
11
services provided in-person; and 
12
(2) provide recommendations with respect to 
13
addressing any disparities identified under subpara-
14
graph (A) or (B) of paragraph (1) in order to bol-
15
ster retention of substance abuse disorder providers 
16
and the provision of substance abuse disorder serv-
17
ices. 
18
SEC. 14. EXPANDING ACCESS TO SUBSTANCE USE DIS-
19
ORDER AND MENTAL HEALTH SERVICES FUR-
20
NISHED THROUGH TELEHEALTH UNDER THE 
21
MEDICARE PROGRAM. 
22
Section 1834(m)(7) of the Social Security Act (42 
23
U.S.C. 1395m(m)(7)) is amended— 
24
00:06 Aug 09, 2020
H7701
25 
•HR 7701 IH
(1) in the paragraph heading, by inserting 
1
‘‘AND
MENTAL
HEALTH
SERVICES’’ after ‘‘SUB-
2
STANCE USE DISORDER SERVICES’’; 
3
(2) by inserting ‘‘or, on or after the first day 
4
after the end of the public health emergency de-
5
scribed in section 1135(g)(1)(B), to an eligible tele-
6
health individual for purposes of diagnosis of a sub-
7
stance use disorder or diagnosis or treatment of a 
8
mental health disorder, as determined by the Sec-
9
retary,’’ after ‘‘as determined by the Secretary,’’. 
10
SEC. 15. ENSURING PARITY FOR MENTAL HEALTH AND AD-
11
DICTION TREATMENT SERVICES. 
12
Title V of the Public Health Service Act (42 U.S.C. 
13
290ll et seq.) is amended— 
14
(1) in part K, by redesignating section 550 (42 
15
U.S.C. 290ee–10), relating to sobriety treatment 
16
and recovery teams, as section 553 and transferring 
17
such section to appear after section 552 in part D; 
18
and 
19
(2) by adding at the end of such part D the fol-
20
lowing: 
21
‘‘SEC. 554. COMPLIANCE WITH MENTAL HEALTH AND AD-
22
DICTION TREATMENT PARITY. 
23
‘‘(a) IN GENERAL.—The Secretary, in coordination 
24
with the Secretary of Labor, shall award grants to, or 
25
00:06 Aug 09, 2020
H7701
26 
•HR 7701 IH
enter into cooperative agreements with, States to ensure 
1
that health insurance issuers in the State comply with sec-
2
tion 2726. 
3
‘‘(b) USE OF GRANT.—A State shall use amounts re-
4
ceived under a grant or cooperative agreement under this 
5
section to— 
6
‘‘(1) establish clear guidelines for parity compli-
7
ance for mental health and substance use disorder 
8
benefits; 
9
‘‘(2) ensure parity compliance during public 
10
health emergencies with best practices for delivering 
11
evidence-based mental health and substance use dis-
12
order treatment, including to ensure virtual, video, 
13
internet, telephonic, and other remote services are 
14
appropriately covered, including alignment with au-
15
thorities, flexibilities, and coverage promulgated by 
16
the Centers for Medicare & Medicaid Services; 
17
‘‘(3) engage with health insurance issuers to en-
18
sure that they comply with the guidelines promul-
19
gated and other provisions of section 2726, including 
20
through audits, market conduct examinations, secret 
21
shopper programs, or other means; 
22
‘‘(4) share information with other States who 
23
receive grants under this section; 
24
00:06 Aug 09, 2020
H7701
27 
•HR 7701 IH
‘‘(5) submit a report to the Secretary and the 
1
Secretary of Labor on information, actions, rec-
2
ommendations, and such other information as such 
3
secretaries may require; and 
4
‘‘(6) publicly post a summary of each report 
5
submitted under paragraph (5) on the websites of 
6
the Department of Health and Human Services and 
7
the Department of Labor. 
8
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 
9
are authorized to be appropriated to carry out this section 
10
$10,000,000 for each of fiscal years 2021 through 2025.’’. 
11
Æ 
00:06 Aug 09, 2020
H7701
